• Home
  • Lenvatinib 4mg
  • Lenvatinib 4mg

Lenvatinib 4mg

52052

Lenvatinib is used for differentiated thyroid cancer that has spread or cannot be removed by surgery and no longer responds well to radioactive iodine.

It is used for advanced renal cell carcinoma, either with pembrolizumab as a first treatment or with everolimus after earlier treatment.

It is also used for unresectable hepatocellular carcinoma and, with pembrolizumab, for certain advanced endometrial cancers after earlier treatment.

Usual adult dose range: 8mg to 24mg once daily, depending on cancer type, body weight, combination treatment, and side effects.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.